Grifols, S.A. (LON:0RDU)

Market Cap	5.75B +35.3%
Revenue (ttm)	6.56B +7.3%
Net Income	325.33M +130.8%
EPS	0.48
Shares Out	n/a
PE Ratio	17.66
Forward PE	10.86
Dividend	0.11 (0.97%)
Ex-Dividend Date	Aug 11, 2025

Volume	245,484
Average Volume	33,218
Open	11.13
Previous Close	11.25
Day's Range	10.92 - 11.36
52-Week Range	7.36 - 13.70
Beta	1.21
RSI	49.76
Earnings Date	Feb 26, 2026

About Grifols

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A an...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1909
• Employees: 23,800
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RDU

Financial Performance

In 2024, Grifols's revenue was 7.21 billion, an increase of 9.41% compared to the previous year's 6.59 billion. Earnings were 156.92 million, an increase of 270.81%.

Financial numbers in EUR